QI
BBIO icon

QS Investors’s BridgeBio Pharma BBIO Stock Holding History

QS Investors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,142
Closed -$223K – 1187
2020
Q4 		$223K Buy
+3,142
New +$152K ﹤0.01% 1081
2020
Q3 		– Sell
-100
Closed -$4K – 1212
2020
Q2 		$4K Buy
+100
New +$3.05K ﹤0.01% 1623

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QS Investors's BBIO Position: Q1 2021 in Review

QS Investors sold out of BridgeBio Pharma (BBIO) in Q1 2021, closing a stake of 3,142 shares — an estimated $223K sold.

QS Investors first reported a position in BBIO in Q2 2020 and held it in 2 quarters. The position peaked at $223K in Q4 2020. 198 funds tracked by Wall St. Rank hold BBIO as of Q1 2021.

  • QS Investors reported no remaining BridgeBio Pharma position as of Q1 2021 after selling out during the quarter.
  • QS Investors sold 3,142 BridgeBio Pharma shares in Q1 2021, an estimated $223K.
  • QS Investors first reported a position in BridgeBio Pharma in Q2 2020 and held it in 2 quarters.
  • QS Investors's BridgeBio Pharma position peaked at $223K in Q4 2020.
  • 198 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2021.

Based on QS Investors's 13F filing for Q1 2021, filed 13 May 2021.